Suppr超能文献

心脏和胸部移植受者的泊沙康唑血药浓度:影响谷浓度的因素及与治疗临床反应的相关性。

Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy.

机构信息

Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.

出版信息

Antimicrob Agents Chemother. 2011 Mar;55(3):1308-11. doi: 10.1128/AAC.01325-10. Epub 2010 Dec 28.

Abstract

Fifty-six serum posaconazole trough levels were measured in 17 cardiothoracic transplant recipients. Initial levels were ≤ 0.5, 0.51 to 0.99, and ≥ 1 μg/ml for 47, 29, and 24% of patients, respectively. Median trough levels associated with therapeutic success were higher than those associated with failure (1.55 versus 0.34 μg/ml; P = 0.006). Patients with levels consistently >0.5 μg/ml were more likely to have successful outcome (P = 0.055). Age ≥ 65 years, oral administration, and absence of proton pump inhibitors were associated with higher levels of posaconazole (P = 0.006, 0.006, and 0.001, respectively).

摘要

在 17 例心胸器官移植受者中测量了 56 份泊沙康唑血药谷浓度。初始浓度分别为 47%、29%和 24%的患者的浓度值为 ≤ 0.5μg/ml、0.51 至 0.99μg/ml 和≥1μg/ml。与治疗成功相关的血药谷浓度中位数高于与治疗失败相关的浓度中位数(1.55μg/ml 比 0.34μg/ml;P=0.006)。浓度持续>0.5μg/ml 的患者更有可能获得成功的治疗结果(P=0.055)。年龄≥65 岁、口服给药和无质子泵抑制剂与泊沙康唑浓度升高相关(P=0.006、0.006 和 0.001)。

相似文献

3
Risk factors for subtherapeutic levels of posaconazole tablet.泊沙康唑片治疗浓度不足的危险因素。
J Antimicrob Chemother. 2017 Oct 1;72(10):2902-2905. doi: 10.1093/jac/dkx228.
5
Relevance of timing for determination of posaconazole plasma concentrations.泊沙康唑血药浓度监测时间的相关性。
Antimicrob Agents Chemother. 2011 Jul;55(7):3621-3. doi: 10.1128/AAC.00062-11. Epub 2011 Apr 18.

引用本文的文献

3
Updated antimicrobial dosing recommendations for obese patients.肥胖患者抗菌药物剂量调整的最新推荐。
Antimicrob Agents Chemother. 2024 May 2;68(5):e0171923. doi: 10.1128/aac.01719-23. Epub 2024 Mar 25.
4
A Review of Population Pharmacokinetic Models of Posaconazole.泊沙康唑群体药代动力学模型评价。
Drug Des Devel Ther. 2022 Oct 20;16:3691-3709. doi: 10.2147/DDDT.S384637. eCollection 2022.

本文引用的文献

1
Age-specific complications among lung transplant recipients 60 years and older.60 岁及以上肺移植受者的年龄特异性并发症。
J Heart Lung Transplant. 2011 Mar;30(3):273-81. doi: 10.1016/j.healun.2010.08.032. Epub 2010 Dec 8.
3
Pharmacokinetic/pharmacodynamic profile of posaconazole.泊沙康唑的药代动力学/药效学特征。
Clin Pharmacokinet. 2010 Jun;49(6):379-96. doi: 10.2165/11319340-000000000-00000.
10
Antifungal therapeutic drug monitoring: established and emerging indications.抗真菌治疗药物监测:既定及新出现的适应证
Antimicrob Agents Chemother. 2009 Jan;53(1):24-34. doi: 10.1128/AAC.00705-08. Epub 2008 Oct 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验